Published : 07 Apr 2025

---

We are glad to announce that Aagami has a new client which is focused on rare disease. 

 

Aagami shall assist the client for possible sale, disposition or equity or assets/Licensing/Co-development agreements with respect to the clients assets and technologies in rare disease.

 

About the Client

Based out of Massachusetts, USA, the client is a clinical stage company focused on rare disease modifying therapies forsickle cell disease & ?-thalassemia patients.

• After closing a $400 million deal for their previous sickle cell asset, the founder started the current company and is developing a new asset to treat sickle cell disease & ?-thalassemia patients.
• They have received investment of $10 million from a popular and reputed Investor company from California. 
• The client is about a year and $15 Million away from being Phase 3 ready. 

Going by the client’s previous success record, Aagami are thrilled to work on the current project and bring success to the client in this assignment. 

 

If your company would like to acquire or partner this rare disease opportunity, please contact us for more details.